All In Biotech

Drug Trial Radar · NCT03255070

A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

A Phase 1, Multicenter, Open-label, Multiple Dose-escalation and Expansion Study of ARX788, as Monotherapy in Advanced Solid Tumors With HER2 Expression

Last checked: Nov 19, 2026Latest source record: Feb 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

106

Actual

Start

Mar 20, 2018

Primary completion

Sep 13, 2023

Study completion Oct 18, 2023

Sponsor

Lead sponsor
Ambrx, Inc.Industry
Sponsor type
Industry
First posted
Aug 21, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This 2-part, Phase 1, open-label study will determine the recommended Phase 2 dose (RP2D) of ARX788 in subjects with advanced HER2 positive cancers and will assess the safety and anticancer activity in breast, gastric and other advanced HER2 positive solid tumors.

Conditions

  • Breast Neoplasms
  • Gastric Neoplasm
  • Solid Tumors

Interventions

  • ARX788Drug

    An antibody drug conjugate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects experiencing adverse events, frequency and seriousness of treatment emergent adverse events (TEAEs)Time frame: Day 1 through 30 days after last dose
  2. Phase 1b: Objective response rate (ORR: complete response + partial response) per imaging assessment based on RECIST version 1.1.Time frame: 36 months

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • USC Norris Cancer Hospital

    Los Angeles, California

  • UCLA Hematology-Oncology

    Santa Monica, California

  • Washington University School of Medicine

    St Louis, Missouri

  • Cleveland Clinic

    Cleveland, Ohio

  • Baylor Sammons Cancer Center

    Dallas, Texas

  • Research Site

    East Albury, New South Wales, Australia

  • Research Site

    North Sydney, New South Wales, Australia

  • Mater Misericordiae Limited

    South Brisbane, Queensland, Australia

  • Princess Alexandria Hospital

    Woolloongabba, Queensland, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • Research Site

    Frankston, Victoria, Australia

  • Research Site

    Nedlands, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.